

JUL 2008
QUESTION 01

Outline three (3) factors that alter the pharmacodynamic response of nondepolarising neuro-muscular blocking drugs and describe the mechanism by which they may occur.

Non depolarising neuromuscular blockers

act by non competitive binding to the nicotinic ACh receptor on the motor end plate
this prevents the action of ACh at the motor end plate and stops muscle excitation
aminosteroids - rocuronium, pancuronium, vecuronium
isoquinolones - atracurium, cisatracurium
the pharmacodynamic response is dependent on the number of receptors occupied
dose dependent according to the laws of mass action
>70% to elicit a response

The factors which alter the response (number of receptors occupied) may be separated into
pharmacodynamic factors
pharmacokinetic factors
pharmaceutical and drug interaction factors

Pharmacodynamic factors

decreased pH increases the affinity of non depolarising NMB
electrolyte disturbances
calcium disturbances affect the release of ACh from the presynaptic terminal (triggered by Ca)
hypercalcaemia results in shortened blockade from pancuronium
magnesium
stabilise membranes and decrease release and sensitivity to ACh
potassium
hypokalaemia leads to membrane hyperpolarisation (decreased drug effect)
hyperkalaemia has the reverse effect
pathology myasthenia gravis patients have defective nACh receptors
eaton-lambert syndrome patients have decreased ACh release
burns - leads to receptor mediated resistance to non depolarising NMBD

Pharmacokinetic factors (affect the amount of drug reaching the receptor)

absorption dose given (higher dose - more receptors occupied)
distribution lipid soluble drugs such as vecuronium may accumulate in lipid rich tissue (esp infusion)
women have higher lipid content which may lead to reduced effect site conc
metabolism hepatic failure may lead to decreased metabolism of a drug - pancuronium
deranged pH changes the metabolism of the isoquinolones which use Hoffmann elim
excretion renally excreted drugs, especially minimally metabolised vecuronium, rocuronium

Pharmaceutical/ drug interactions

storage of the drug (isoquinolones must be stored at 4 degrees to maintain potency)
Increase effect
aminoglycosides - decreased prejunctional ACh release
volatile anaesthetics - mechanism not well understood
frusemide - potassium effect, may interfere with cAMP and ACh release
decrease effect
anticonvulsants - may develop resistance to pancuronium, vecuronium